Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DRUG: Dragon Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: FRANK J CATALANO who wrote (4)	2/4/2003 1:24:14 PM
From: Crossy	Read Replies (2) \| Respond to of 28

OK, as I said I studied their current 10K and what I saw there really raised my interest: 1) Big Pharma background CEO 2) Not a development stage "research" oriented biotech shop but a marketer and maker of global-big-drugs in markets where no patents apply. This makes Dragon way less risky than the typical research-based biotech company without running revenes to draw from --> recurring revenues 3) Advanced Genetic engineering manufacturing techniques yield lowcost position (see PRs and 10K describing their gene sequencing production models of 3) EPO, Trombopojetin and Lymphozyte Growth factor --> low cost position 4) Once the respective patents in developed countries run out, DRUG could enter the respective market as a generics supplier. They specifically mention this with regard to EPO in 2004-2005 -> added "generics" opportunities in major markets over time can only ask everyone to do the necessary DD, especially read the important filings (10K, 8K) best regards to all CROSSY

To: FRANK J CATALANO who wrote (4)	2/20/2003 5:43:20 PM
From: Crossy	Respond to of 28

Dragon Pharma (DRUG.OB)- News : Key Hiring VP of Marketing announced Now this is a great HR strategy. Hire the a guy with marketing responsibility back then at Amgen to promote the generic version with all his ties and informal channels once the patent expired.. Dragon Pharmaceuticals Appoints James Harris as VP of Sales and Marketing VANCOUVER, Feb. 20 - Dragon Pharmaceuticals Inc. (TSX: DDD; OTC BB: DRUG) is pleased to announce that it has appointed James Harris as VP of Sales and Marketing, replacing Robert Walsh. He will be responsible for increasing the company's sales and marketing effort in our existing markets outside of China (India, Egypt, Peru and Brazil) and accelerating the introduction of Dragon's erythropoietin in the other out licensed markets, which cover most of the territories outside Europe, North America and Japan. He will also prepare the company for entry into the European market. Mr. Harris has over 22 years of experience within the above field in several capacities of increasing responsibility. Prior to Dragon, Mr. Harris has been a consultant in biotech and pharmaceuticals, and he has worked with various firms ranging from large multinationals to small generic companies. Mr. Harris spent eight years with Amgen most recently as a National Accounts Manager and ten years with Bayer in various sales and marketing capacities. Mr. Harris has been associated with numerous major product launches, including the launches of EPO(Epogen®), GCSF(Neupogen®), and Intravenous Immune Globulin, IVIG (Gamimune®). He has also assisted the field sales organization with training and development efforts. He also serves as the Assistant Area Chair Department of Graduate Business and Management at the University of Phoenix. Mr. Harris obtained a B.A. in Political Science from Wright State University and an M.B.A., in Finance from Long Island University. Dr. Wick, President of Dragon Pharmaceuticals said, "James Harris brings to Dragon the extensive sales and marketing experience necessary to further develop our international sales. We are excited to have him as part of the company." Robert Walsh has been appointed as Director of Corporate Development, an area in which he has had a keen interest since beginning with Dragon three years ago. "I am pleased to fill this position with a staff member who is experienced, very knowledgeable in the field of technology and, more specifically, in all aspects of erythropoietin," said Dr. Wick, "I am determined to realign the company resources to meet our objective of profitability in 2003. This change in management is a clear signal of how we are meeting the identified priorities and the dynamics with which the company is determined to confront the future." About Dragon Pharmaceuticals Dragon Pharmaceuticals Inc. is a fully integrated, international biopharmaceutical corporation engaged in the discovery, development and commercialization of genetically engineered human proteins for therapeutic use. Based on its proprietary protein expression technology, Dragon believes that it has become one of the world's lowest cost producers of Erythropoietin (EPO) - a breakthrough drug that has revolutionized the treatment of severe anemia with estimated worldwide sales of US$6 billion in 2001. Dragon is also applying its platform technology to the development of other branded as well as novel protein drugs. For further information, please call Tel: (604) 669-8817 or Fax: (604) 669-4243 or visit our web site at www.dragonbiotech.com